AC Immune (ACIU) News Today → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free ACIU Stock Alerts $3.38 +0.08 (+2.42%) (As of 12:45 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 5:21 AM | ft.comTakeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccineMay 13 at 7:20 PM | msn.comAlzheimer’s vaccine licensing deal boosts AC ImmuneMay 13 at 7:20 PM | finance.yahoo.comSector Update: Health Care Stocks Mixed Late AfternoonMay 13 at 3:48 PM | investorplace.comACIU Stock Earnings: AC Immune Misses EPS for Q1 2024May 13 at 9:35 AM | investorplace.comWhy Is AC Immune (ACIU) Stock Up 45% Today?May 13 at 8:24 AM | marketwatch.comAC Immunity Shares Soar on Exclusive License Deal with TakedaMay 13 at 8:24 AM | sfgate.comAC Immune: Q1 Earnings SnapshotMay 13 at 8:24 AM | finance.yahoo.comTakeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment CandidateMay 13 at 6:05 AM | globenewswire.comAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 13 at 6:00 AM | businesswire.comAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseMay 13 at 6:00 AM | globenewswire.comAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseMay 9, 2024 | americanbankingnews.comAC Immune (NASDAQ:ACIU) Upgraded to "Hold" at StockNews.comMay 9, 2024 | marketbeat.comAC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.comStockNews.com upgraded AC Immune from a "sell" rating to a "hold" rating in a report on Wednesday.April 27, 2024 | money.usnews.comAC Immune SAApril 18, 2024 | finance.yahoo.comAC Immune SA (ACIU)April 11, 2024 | finance.yahoo.comWe Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business GrowthMarch 20, 2024 | wsj.comAC Immune S.A.March 18, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AC Immune in a research report on Friday.March 15, 2024 | markets.businessinsider.comBuy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated ApprovalMarch 15, 2024 | finance.yahoo.comFurther weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%March 14, 2024 | finance.yahoo.comACIU Mar 2024 2.500 putMarch 14, 2024 | globenewswire.comAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateMarch 10, 2024 | marketbeat.comAC Immune (ACIU) to Release Quarterly Earnings on MondayAC Immune (NASDAQ:ACIU) will be releasing earnings on Monday, March 11, Yahoo Finance reports.March 8, 2024 | marketbeat.comLeerink Partnrs Comments on AC Immune SA's Q1 2024 Earnings (NASDAQ:ACIU)AC Immune SA (NASDAQ:ACIU - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of AC Immune in a report issued on Wednesday, March 6th. Leerink Partnrs analyst M. Goodman expects that the company will earn ($0.18) per share foFebruary 22, 2024 | finanznachrichten.deAC Immune SA: AC Immune Announces Upcoming Presentations at AD/PD 2024February 22, 2024 | finance.yahoo.comAC Immune Announces Upcoming Presentations at AD/PD™ 2024February 22, 2024 | globenewswire.comAC Immune Announces Upcoming Presentations at AD/PD™ 2024February 21, 2024 | insidermonkey.com5 Little-Known Penny Stocks With Massive Upside PotentialFebruary 20, 2024 | finance.yahoo.comACIU May 2024 2.500 callFebruary 20, 2024 | finance.yahoo.comACIU Aug 2024 2.500 callFebruary 14, 2024 | marketbeat.comShort Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 14.1%AC Immune SA (NASDAQ:ACIU - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 480,600 shares, a decrease of 14.1% from the January 15th total of 559,300 shares. Based on an average daily trading volume, of 127,500 shares, the short-interest ratio is presently 3.8 days. Currently, 0.9% of the company's stock are sold short.February 13, 2024 | investing.comAC Immune Ltd (ACIU)February 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for AC Immune SA Amid Promising Immunotherapy Program DevelopmentsJanuary 30, 2024 | finance.yahoo.comDown -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a TurnaroundJanuary 22, 2024 | finanznachrichten.deAC Immune SA: AC Immune to Regain Global Rights to Crenezumab and SemorinemabJanuary 22, 2024 | finance.yahoo.comAC Immune to Regain Global Rights to Crenezumab and SemorinemabJanuary 18, 2024 | finance.yahoo.comAC Immune (ACIU) is a Great Momentum Stock: Should You Buy?January 8, 2024 | finance.yahoo.com5 Small-Cap Stocks to Play the January EffectJanuary 3, 2024 | msn.comAC Immune issues updates on Phase 2 studies, cash runwayJanuary 3, 2024 | finance.yahoo.comAC Immune (ACIU) Upgraded to Buy: Here's WhyJanuary 3, 2024 | finance.yahoo.comAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesDecember 15, 2023 | msn.comAC Immune Alzheimer's drug advanced into Phase 2b testingDecember 15, 2023 | finance.yahoo.comAC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b TrialDecember 15, 2023 | finance.yahoo.comAC Immune Announces Pricing of Underwritten Offering of Common SharesDecember 13, 2023 | finance.yahoo.comAC Immune SA's (NASDAQ:ACIU) top owners are private equity firms with 37% stake, while 25% is held by individual investorsDecember 11, 2023 | finance.yahoo.comAlzheimer's Disease Space Evolves in 2023: Stocks in FocusDecember 5, 2023 | finance.yahoo.comIs it a Good Idea to Invest in AC Immune (ACIU) Stock Now?December 1, 2023 | finance.yahoo.comAC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFONovember 20, 2023 | finance.yahoo.comFOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 17, 2023 | morningstar.comAC Immune SA ACIU Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. ACIU Media Mentions By Week ACIU Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACIU News Sentiment▼0.920.57▲Average Medical News Sentiment ACIU News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACIU Articles This Week▼151▲ACIU Articles Average Week Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Conduit Pharmaceuticals News Today Veru News Today Foghorn Therapeutics News Today Emergent BioSolutions News Today 23andMe News Today Puma Biotechnology News Today Zevra Therapeutics News Today Aldeyra Therapeutics News Today Werewolf Therapeutics News Today G1 Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACIU) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
